CORRECTION

Pathol. Oncol. Res., 30 January 2023

Volume 29 - 2023 | https://doi.org/10.3389/pore.2023.1610989

Corrigendum: Case report: Potential predictive value of MMR/MSI status and PD-1 expression in immunotherapy for urothelial carcinoma

    YM

    Yu-Ting Ma 1

    YL

    Yan Li 2

    LY

    Li Yan 3

    FH

    Fang Hua 4

    DW

    Dong-Guan Wang 3

    GX

    Guo-Ying Xu 5

    HY

    Hong-Lan Yang 2

    YX

    Ying-Jie Xue 1

    YQ

    Ye-Jun Qin 1

    DS

    Dan Sha 6

    HN

    Hao Ning 7

    MZ

    Miao-Qing Zhao 8*

    ZY

    Zhi-Gang Yao 1*

  • 1. Department of Pathology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, China

  • 2. Departmentof Oncology, Dongying City People’s Hospital, Dongying, China

  • 3. Department of Pathology, Dongying City People’s Hospital, Dongying, China

  • 4. Department of Microbiology and Immunology, Tulane University, New Orleans, LA, United States

  • 5. Department of Urology Surgery, Dongying Hospital of Traditional Chinese Medicine, Dongying, China

  • 6. Department of Oncology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, China

  • 7. Department of Urology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, China

  • 8. Department of Pathology, Shandong Cancer Hospital and Institute, Shandong First Medical University, Shandong Academy of Medical Sciences, Jinan, China

Article metrics

759

Views

477

Downloads

In the published article there was an error in the author list. Authors Hong-Lan Yang and Yan Li were listed in the wrong order. The equal contribution of the first co-authors was not included. The corrected author list appears below:

Yu-Ting Ma1‡, Yan Li2‡, Li Yan3‡, Fang Hua4, Dong-Guan Wang3, Guo-Ying Xu5, Hong-Lan Yang2, Ying-Jie Xue1, Ye-Jun Qin1, Dan Sha6, Hao Ning7, Miao-Qing Zhao8* and Zhi-Gang Yao1*

ORCID: Zhi-Gang Yao, orcid.org/0000-0002-8034-6524

Contributed equally to this work

The authors apologize for these errors and state that they do not change the scientific conclusions of the article in any way. The original article has been updated.

Summary

Keywords

immunotherapy, microsatellite instability, immune checkpoint inhibitors, urothelial carcinoma, lynch syndrome, PD-1/PD-L1

Citation

Ma Y-T, Li Y, Yan L, Hua F, Wang D-G, Xu G-Y, Yang H-L, Xue Y-J, Qin Y-J, Sha D, Ning H, Zhao M-Q and Yao Z-G (2023) Corrigendum: Case report: Potential predictive value of MMR/MSI status and PD-1 expression in immunotherapy for urothelial carcinoma. Pathol. Oncol. Res. 29:1610989. doi: 10.3389/pore.2023.1610989

Received

04 December 2022

Accepted

12 January 2023

Published

30 January 2023

Volume

29 - 2023

Edited by

Pathology & Oncology Research Editorial Office, Frontiers Media SA, Switzerland

Updates

Copyright

*Correspondence: Zhi-Gang Yao, ; Miao-Qing Zhao,

‡These authors have contributed equally to this work

ORCID: Zhi-Gang Yao, orcid.org/0000-0002-8034-6524

Disclaimer

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Cite article

Copy to clipboard


Export citation file


Share article